The Clinical Effects of Laser Acupuncture on Hospitalized Patients With Severe COVID-19: A Randomized Clinical Trial

被引:0
|
作者
Shojaeddin, Arista [1 ]
Fatemi, Alireza [2 ]
Razzaghi, Zahra [1 ]
Pishgahi, Mehdi [3 ]
Sherafat, Somayeh Jahani [1 ]
Razzaghi, Mohammadreza [1 ]
Shahrzad, Mohamad Karim [4 ]
Anaraki, Nafiseh [4 ]
Salehi, Chiman [4 ]
Amiri, Aslan [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Cardiol Dept, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Internal Med & Endocrinol Dept, Tehran, Iran
关键词
Laser acupuncture; Laser therapy; COVID-19; Severity; THERAPY LLLT; PAIN; IRRADIATION; IL-1-BETA; RELEVANCE; ASTHMA; BLIND; LUNG; ACTS;
D O I
10.34172/jlms.2023.14
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The coronavirus disease (COVID-19) was extended to the entire population in China and around the world, and its mortality rate was about 3.4%. The impact of laser therapy on chronic respiratory diseases has been shown in previous studies. This study was aimed at examining the effects of laser acupuncture (LA) on patients with severe COVID-19. Methods: In the present study, 60 patients with a positive reverse transcription-polymerase chain reaction (RT-PCR) test were assigned to the intervention and control groups (30 patients in each group). The intervention group was treated with LA, that is, laser light with low energy on acupuncture points, once a day for five consecutive days. Results: The participants' mean age in the intervention and control groups was 48.96 +/- 12.65 and 53.16 +/- 12.28 respectively; 70% of the patients were male and 30% of them were female. IL6 had a significant reduction in the intervention group (P value = 0.038) in comparison with the control group (P value = 0.535). Furthermore, the mean admission time in the control group was significantly higher than that in the intervention group (P value = 0.047). However, the mortality rate in the intervention group was zero, but three patients in the control group died. Conclusion: Our study showed that LA can be used as supportive therapy for routine treatment in patients with severe COVID-19. Moreover, due to LA safety and it's low cost, it could be recommended as an adjuvant to conventional therapy in patients interested in treating their disease with such a method.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial
    Jelodar, Mohsen Gholinataj
    Rafieian, Shahab
    Saghafi, Fatemeh
    Zedegan, Navid Hadad
    Birjandi, Behnaz
    Rafieian, Shiva
    Dini, Azadeh Allah
    Dehghanpour, Hanieh
    Khalaj, Fatemeh
    Zare, Samira
    Chenari, Hanieh Dehghan
    Hajimaghsoudi, Majid
    Sohrevardi, Seyed Mojtaba
    Mirzaei, Samaneh
    Jamialahmadi, Tannaz
    Atkin, Stephen L.
    Sahebkar, Amirhossein
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
  • [42] Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19
    Ageno, Walter
    Cogliati, Chiara
    Perego, Martina
    Girelli, Domenico
    Crisafulli, Ernesto
    Pizzolo, Francesca
    Olivieri, Oliviero
    Cattaneo, Marco
    Benetti, Alberto
    Corradini, Elena
    Bertu, Lorenza
    Pietrangelo, Antonello
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (04) : 989 - 996
  • [43] Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial
    Gomaa, Adel A.
    Mohamed, Hamdy S.
    Abd-ellatief, Rasha B.
    Gomaa, Mohamed A.
    Hammam, Doaa S.
    INFLAMMOPHARMACOLOGY, 2022, 30 (02) : 477 - 486
  • [44] Utilizing the sublingual form of squalene in COVID-19 patients: a randomized clinical trial
    Ebrahimi, Mahmoud
    Farhadian, Nafiseh
    Soflaei, Sara Saffar
    Amiri, Alireza
    Tanbakuchi, Davoud
    Oskooee, Rozita Khatamian
    Karimi, Mohammad
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [45] Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
    Duarte, Mariano
    Pelorosso, Facundo
    Nicolosi, Liliana N.
    Salgado, M. Victoria
    Vetulli, Hector
    Aquieri, Analia
    Azzato, Francisco
    Castro, Marcela
    Coyle, Javier
    Davolos, Ignacio
    Criado, Ignacio Fernandez
    Gregori, Rosana
    Mastrodonato, Pedro
    Rubio, Maria C.
    Sarquis, Sergio
    Wahlmann, Fernando
    Rothlin, Rodolfo P.
    ECLINICALMEDICINE, 2021, 37
  • [46] Utilizing the sublingual form of squalene in COVID-19 patients: a randomized clinical trial
    Mahmoud Ebrahimi
    Nafiseh Farhadian
    Sara Saffar Soflaei
    Alireza Amiri
    Davoud Tanbakuchi
    Rozita Khatamian Oskooee
    Mohammad Karimi
    Scientific Reports, 14
  • [47] Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial
    Elmekaty, Eman Zeyad I.
    Maklad, Aya
    Abouelhassan, Rawan
    Munir, Waqar
    Ibrahim, Mohamed Izham Mohamed
    Nair, Arun
    Alibrahim, Rim
    Iqbal, Fatima
    Al Bishawi, Ahmad
    Abdelmajid, Alaaeldin
    Aboukamar, Mohamed
    Hadi, Hamad Abdel
    Khattab, Mohammed Abu
    Al Soub, Hussam
    Al Maslamani, Muna
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [48] Olfactory rehabilitation in non-severe COVID-19 patients: a randomized double-blinded clinical trial
    Serrano, T.
    Antonio, M.
    Giacomin, L.
    Ribeiro, J. D.
    Sakano, E.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [49] Effect of degalactosylated bovine glycoprotein formulations MAF and M сapsules on lymphopenia and clinical outcomes in hospitalized COVID-19 patients: a randomized clinical trial
    Inui, Toshio
    Kruglova, Oksana
    Martynenko, Olga
    Martynenko, Kostiantyn
    Tieroshyn, Vadym
    Gavrylov, Anatoliy
    Kubo, Kentaro
    Yamakage, Hajime
    Kutsyn, Borys
    Kubashko, Alla
    Veklych, Zoryana
    Terashima, Yurika
    Mette, Martin
    Kutsyna, Galyna
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [50] Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial
    Adel A. Gomaa
    Hamdy S. Mohamed
    Rasha B. Abd-ellatief
    Mohamed A. Gomaa
    Doaa S. Hammam
    Inflammopharmacology, 2022, 30 : 477 - 486